title: Gynecomastia in patients with prostate cancer: update on treatment options.
abstract: Non-steroidal antiandrogen monotherapy offers potential quality of life benefits over other treatment modalities in patients with prostate cancer. Nevertheless, gynecomastia and breast pain still represent the most bothersome side effects during this treatment. In this update article, recent advances in the management options for gynecomastia/breast pain caused by hormonal manipulation are reviewed and critically analyzed.
authors.affiliation: Clinica Urologica, Seconda Università degli Studi, Napoli, Italy. ricautor@tin.it
authors.forename: R
authors.initials: R
authors.lastname: Autorino
authors.forename: S
authors.initials: S
authors.lastname: Perdonà
authors.forename: M
authors.initials: M
authors.lastname: D'Armiento
authors.forename: M
authors.initials: M
authors.lastname: De Sio
authors.forename: R
authors.initials: R
authors.lastname: Damiano
authors.forename: L
authors.initials: L
authors.lastname: Cosentino
authors.forename: G
authors.initials: G
authors.lastname: Di Lorenzo
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D015897:Comorbidity; D005500:Follow-Up Studies; D006177:Gynecomastia / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D006801:Humans; D008297:Male; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D012720:Severity of Illness Index; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen